hepatitis C

How to manage hepatitis C patients under MACRAImproved documentation and data can not only improve wellness, but also a practice’s value scores
Oral specialty drug options on the horizon
Oral specialty drug options on the horizonAs more specialty drugs are approved, cost control strategies are key.
Medical marijuana update: Top 3 things health execs should knowHere’s what you need to know about medical marijuana laws, and what they mean for the healthcare system.
Controversy surrounds Exondys 51 approval: What to knowNew medicine for Duchenne muscular dystrophy raises questions. Here’s whose covering it and why.
Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patientsCost burden prompts payers to consider appropriate utilization
CDC issues advisory on Zika testingThe latest on testing guidelines for Zika from the CDC. Plus: Are corticosteroids effective when administered only hours before delivery? Also, a look at the prevalence of hepatitis C among pregnancy women in the United States.
Tripled Hep C Rates Blamed on Opioid Crisis
Tripled Hep C Rates Blamed on Opioid CrisisThe surge in HCV transmission rates is being blamed on the opioid epidemic.
Hep C drugs approved for kidsFDA approved supplemental applications for 2 primary hepatitis C medications to be used in children for the first time.
Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Safety Concerns Over Some Hepatitis C DrugsThe ISMP has issued a report that links several direct-acting antiviral agents for hepatitis C to serious adverse side effects. But drug makers take issue.